Barvaliya MJ

Iskandar JW

Membrillo de Novales FJ

Rosini JM

 The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of prevention, and promote reporting of ADRs to the US Food and Drug Administration's (FDA's) MedWatch program (800-FDA-1088). If you have reported an interesting, preventable ADR to MedWatch, please consider sharing the account with our readers. </jats:p

Michael A. Mancano

Crossref

Hospital Pharmacy

Ziprosidone-Induced Transient Agranulocytosis; Delayed Onset of Cardiac Adverse Effects with Fingolimod; Telmisartan-Induced Myotoxicity; Severe Dilated Cardiomyopathy Induced by Adalimumab and Ustekinumab

Ziprosidone-Induced Transient Agranulocytosis; Delayed Onset of Cardiac Adverse Effects with Fingolimod; Telmisartan-Induced Myotoxicity; Severe Dilated Cardiomyopathy Induced by Adalimumab and Ustekinumab

Abstract

Similar works

Full text

Available Versions

Crossref